Atlas Venture Life Science Advisors, LLC has filed a Form 13F-HR with the Securities and Exchange Commission, disclosing its equity securities portfolio as of the close of business on September 30, 2026. The filing reports the firm’s holdings in various common stocks, with the total number of securities listed as 9.
The filing identifies Disc Medicine, Inc. as the largest holding, with an ownership of 1,384,025 shares. Other significant positions include Kymera Therapeutics, Inc., with 2,847,541 shares, and Kailera Therapeutics, Inc., with 5,171,282 shares. Obsidian Therapeutics, Inc. holds 4,503,149 shares, while Sionna Therapeutics, Inc. holds 2,995,602 shares.
The report also lists positions in Dyne Therapeutics, Inc., Korro Bio, Inc., Q32 Bio, Inc., and Odyssey Therapeutics, Inc. The total number of shares listed for all holdings combined is 25,460,410.
